135 related articles for article (PubMed ID: 37226898)
21. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
[TBL] [Abstract][Full Text] [Related]
23. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
24. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
[TBL] [Abstract][Full Text] [Related]
25. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
[TBL] [Abstract][Full Text] [Related]
26. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
[TBL] [Abstract][Full Text] [Related]
27. Renal Medullary Carcinoma: Establishing Standards in Practice.
Beckermann KE; Sharma D; Chaturvedi S; Msaouel P; Abboud MR; Allory Y; Bourdeaut F; Calderaro J; de Cubas AA; Derebail VK; Hong AL; Naik RP; Malouf GG; Mullen EA; Reuter VE; Roberts CWM; Walker CL; Wood CG; DeBaun MR; Van Poppel H; Tannir NM; Rathmell WK
J Oncol Pract; 2017 Jul; 13(7):414-421. PubMed ID: 28697319
[TBL] [Abstract][Full Text] [Related]
28. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
[TBL] [Abstract][Full Text] [Related]
29. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
[TBL] [Abstract][Full Text] [Related]
30. Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity.
Jones TM; Espitia CM; Chipollini J; Lee BR; Wertheim JA; Carew JS; Nawrocki ST
Cancer Res Commun; 2023 Feb; 3(2):245-257. PubMed ID: 36860653
[TBL] [Abstract][Full Text] [Related]
31. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
33. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
34. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Faessel H; Nemunaitis J; Bauer TM; Lockhart AC; Faller DV; Sedarati F; Zhou X; Venkatakrishnan K; Harvey RD
Br J Clin Pharmacol; 2019 Jul; 85(7):1464-1473. PubMed ID: 30845347
[TBL] [Abstract][Full Text] [Related]
35. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
[TBL] [Abstract][Full Text] [Related]
36. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
[TBL] [Abstract][Full Text] [Related]
37. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
38. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
Faessel HM; Mould DR; Zhou X; Faller DV; Sedarati F; Venkatakrishnan K
Br J Clin Pharmacol; 2019 Nov; 85(11):2568-2579. PubMed ID: 31355467
[TBL] [Abstract][Full Text] [Related]
40. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
